Incorporating Somatuline’s generic approval headwinds
07/01/22 -"Despite easing pandemic headwinds and recovering underlying markets, our EPS estimates reset lower as we take on board Somatuline’s sales erosion on account of the approval of its generic in the US. ..."
Pages
53
Language
English
Published on
07/01/22
You may also be interested by these reports :
01/07/25
Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...
26/06/25
Downside for 1H25E consensus – FY25E consensus should be fine – Mid-term potential reiterated
24/06/25
Just like Big Pharmas in aggregate, Sanofi’s (Buy; France) shares have gone nowhere over the last two years. After collapsing by c.19% in a day in ...
12/06/25
Only a month ago we were lamenting the weakness of Pharmas, the second larget sector by market cap. The tide may have turned, strangely as part ...